SCHEMBL6523449

SCHEMBL6523449

COc1nc(-c2cc3cc[nH]c(=O)c3c(Nc3ccc(C4CCN(CCC#N)CC4)cc3)n2)cnc1N

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 16/20 0.56
EGFR P00533 1/20 0.36
JAK1 P23458 3/20 0.36
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158545 0.91 ZAP70 (0.56) ZAP70JAK1JAK2
SCHEMBL1049153 0.89 ZAP70 (0.66) ZAP70EGFRJAK1
SCHEMBL1045437 0.85 ZAP70 (0.61) ZAP70JAK1
SCHEMBL1043393 0.84 ZAP70 (0.57) ZAP70JAK1JAK2
SCHEMBL1158513 0.83 ZAP70 (0.62) ZAP70JAK1JAK2
SCHEMBL1048857 0.83 ZAP70 (0.80) ZAP70JAK1JAK2
SCHEMBL1160075 0.80 ZAP70 (0.63) ZAP70JAK1JAK2
SCHEMBL1049818 0.79 ZAP70 (0.62) ZAP70
SCHEMBL1048294 0.78 ZAP70 (0.62) ZAP70
SCHEMBL1158037 0.78 ZAP70 (0.58) ZAP70JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN ZAP70 5/4885EGFR 1168/4885JAK1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.